IR News
Mar. 18, 2020Print(PDF/83KB)Corporate
Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position
Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura) today announced the following change in Executive Officer and other key position, effective April 1, 2020:
I. Change in Executive Officer
Changes in the positions assumed by Executive Officers (effective April 1, 2020)
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Executive Officer Drug Development Division Executive Director, Drug Development Division Deputy Executive Director, Corporate Regulatory Compliance & Quality Assurance Division Deputy Head of Japan Business Unit |
Executive Director, Drug Development Division | Koichi Kozuki |
* Added the underlined part in the change in Executive Officer announced in our press release dated March 3, 2020.
II. Change in Personnel (effective April 1, 2020)
| Position as of April 1, 2020 | Current position | Name |
|---|---|---|
| Senior Director, Analytical Research & Development Laboratories | Director, Project Planning & Management Group, Technology Research & Development Management | Yutaka Nishihara |